Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
9 hedge funds and large institutions have $407K invested in Avenue Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
141% more capital invested
Capital invested by funds: $169K → $407K (+$238K)
31% less funds holding
Funds holding: 13 → 9 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$436K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$165K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$17.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.91K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$41 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$26.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.69K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.83K |
| 5 |
HF
HRT Financial
New York
|
-$6K |
ATXI Hedge Fund Activity: Q2 2024 in Review
9 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2024, worth a combined $407K — up 141% from $169K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATXI and 4 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $436K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $26.3K sold.
- 9 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2024, down from 13 in Q1 2024.
- Funds reported $407K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2024, up 141% quarter-over-quarter.
- 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2024 and 8 closed out, a net change of -4 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2024 was Armistice Capital, an estimated $436K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2024 was Two Sigma Securities, an estimated $26.3K sold.
Based on aggregated 13F filings for Q2 2024.